Spectral Medical Third Quarter 2024 Earnings: CA$0.035 loss per share (vs CA$0.012 loss in 3Q 2023)
Spectral Medical (TSE:EDT) Third Quarter 2024 Results
Key Financial Results
- Revenue: CA$502.0k (up 26% from 3Q 2023).
- Net loss: CA$10.00m (loss widened by 207% from 3Q 2023).
- CA$0.035 loss per share (further deteriorated from CA$0.012 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Spectral Medical Earnings Insights
Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 2 years, compared to a 58% growth forecast for the Biotechs industry in Canada.
Performance of the Canadian Biotechs industry.
The company's shares are down 5.1% from a week ago.
Risk Analysis
It is worth noting though that we have found 5 warning signs for Spectral Medical (3 are a bit unpleasant!) that you need to take into consideration.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSX:EDT
Spectral Medical
Focuses on the development and commercialization of products for the treatment of septic shock in the United States, Italy, Ireland, and internationally.
Moderate with concerning outlook.
